Nipro Announces Major Expansion with New Medical Device Manufacturing Facility in Greenville, North Carolina, USA

BOC Sciences Chemistry Scholarship Program of 2024 Announced

BOC Sciences is pleased to announce its new Scholarship Program aimed at supporting college students pursuing degrees in chemistry-related fields. This prestigious scholarship awards $1,000 annually to help these aspiring chemists achieve their academic goals and make a difference in the scientific community.

Sapio Sciences Launches Partner Program to Accelerate Research and Diagnostics

Sapio Sciences, the science-aware™ lab informatics platform, today announced the Sapio Sciences Partner Program. The program provides a growing partner ecosystem of technology vendors, services companies, and resellers with the tools, training, support, and marketing services to deliver solutions that empower scientists.

Intelliguard Unveils Enhanced Suite of Medication Management and Data Intelligence Solutions to Ensure an Environment of Safety for Hospitals and Patients

Intelliguard, a proven provider of medication management and data intelligence solutions, has unveiled its Mira Ecosystem, a reimagined product line of innovative and integrated solutions for hospitals and healthcare systems that support increased patient safety and operational efficiency.

Integrated DNA Technologies Announces New Licensing Agreement with SeQure Dx to Advance CRISPR-based Therapeutics

IDT inks licensing agreement with SeQure Dx to support cell and gene therapy developers through all stages of their CRISPR-based therapeutic programs.

Avallano releases ProtocolCopilot™: Powering Clinical Research with AI-driven Protocol Assistance

Avallano is launching ProtocolCopilot™, an innovative AI-driven clinical research protocol assistant designed to transform the way biopharmaceutical companies and clinical research sites manage and interact with complex clinical trial protocols.

Optibrium Appoints James Halle as Chief Commercial Officer

Optibrium, a leading developer of software and AI solutions for drug discovery and molecular design, today announced the appointment of James Halle as Chief Commercial Officer (CCO). James brings extensive software experience in the pharma industry and will guide the commercial success of the company.

1upHealth Achieves HITRUST Implemented, 1-year (i1) Certification to Manage Data Protection and Mitigate Cybersecurity Threats

Synexa Life Sciences Enrols in My Green Lab Certification Program

Synexa Life Sciences has announced its enrolment in the My Green Lab Certification Program.

Surfix Diagnostics, the Netherlands Cancer Institute and CRCbioscreen join forces to validate biomarkers for colorectal cancer screening

Surfix Diagnostics alongside the Netherlands Cancer Institute (NKI) and CRCbioscreen, announced a collaboration aimed at enhancing colorectal cancer (CRC) screening methods.

ZYMO RESEARCH LAUNCHES THE OMICS DISCOVERY GRANT TO ADVANCE RNA-SEQ RESEARCH

https://www.zymoresearch.com/blogs/press-releases/omics-discovery-grant-launch Apply for Zymo Research's Omics Discovery Grant for cutting-edge RNA-Seq tools worth $4000.

Personalized Obesity Care Genetic Testing Available to Women in New Phenomix Sciences and Hello Alpha Partnership

The first-of-its-kind collaboration combines personalized genetic insights with evidence-based treatments to provide accessible and effective obesity care for women

Cotiviti’s Quality Intelligence Earns NCQA Certified Measures Status for HEDIS® Measurement Year 2024

Pascal Piedbois, MD, PhD joins One2Treat as Chief Medical Officer to advance patient-centric innovation in clinical trial design and market access

Pascal Piedbois, MD, PhD joins One2Treat as Chief Medical Officer to advance patient-centric innovation in clinical trial design and market access. One2Treat reflects patient priorities in a single multi-facet treatment assessment, reducing trial sample size and accelerating patient access to new treatments.

SMi Systems appoints Dr Stefan Hamill as VP of Strategy

SMi Systems announces the appointment of Dr Stefan Hamill as its Vice President of Strategy. Dr Hamill was formerly a senior analyst at investment banks Numis (now Deutsche Numis) and Peel Hunt, both of which he helped transform into #1 ranked franchises in UK Life Sciences.

DoseMe Achieves HITRUST Risk-Based, 2-year (r2) Certification

DoseMe, a leading provider of model-informed precision dosing (MIPD), announced today it has earned certified status by HITRUST for information security. HITRUST Risk-based, 2-year (r2) Certification demonstrates that the organization’s DoseMeRX has met demanding regulatory compliance and industry-defined requirements and is appropriately managing risk. This achievement places DoseMe in an elite group of organizations worldwide that have earned this certification. By including federal and state regulations, standards, and frameworks and incorporating a risk-based approach, the HITRUST Assurance Program helps organizations address security and data protection challenges through a comprehensive and flexible framework of prescriptive and scalable security controls. DoseMe remains the only model informed precision dosing platform to achieve the r2 Certification.

ChargePoint Technology strengthens its global presence by establishing a localised team in India to support the growing pharma manufacturing market

CPHI South East Asia opens as growth prospects outlined for pharmaceutical development in Vietnam, Thailand and Cambodia

CG Life Forms Strategic Communications Group to Integrate Corporate, Scientific and Medical Communications and Social Media Services

Optibrium Demonstrates Accelerated Lead Optimisation in Complex Agrochemical Development

Optibrium announced the publication of a peer-reviewed study in Journal of Computer-Aided Molecular Design, ‘From UK-2A to florylpicoxamid: Active learning to identify a mimic of a macrocyclic natural product’. The paper demonstrates the successful application of the QuanSA (Quantitative Surface-field Analysis) method, part of Optibrium’s BioPharmics platform for 3D molecular design, to accelerate the lead optimisation of a complex macrocyclic natural product during agrochemical development. By significantly reducing the number of synthetic steps required during optimisation, the study supports the commercial viability of complex macrocyclic compounds.